MannKind focuses on the development and commercialization of innovative inhaled therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/06/25 | $500,000,000 | Strategic |
Blackstone | undisclosed |
